LINC01916

Across TCGA pan-cancer cohorts, LINC01916 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated LINC01916 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LINC01916 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LINC01916 expression acts as an unfavorable survival marker, although some lineages such as ACC and UCS show a favorable association.

LUAD, KICH, and HNSC are the cancer types where LINC01916 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	IV	0.131	0.740	<.001	102	view →
KICH	OS	Tertile	All	0.161	0.881	<.001	72	view →
HNSC	OS	Tertile	II,III,IV	0.378	0.717	<.001	66	view →
READ	OS	Tertile	II,III,IV	0.171	0.681	.004	54	view →
ACC	DFS	Tertile	All	1.000	0.446	.002	45	view →
LUSC	OS	Tertile	III,IV	0.147	0.664	.028	36	view →
ESCA	OS	Tertile	All	0.198	0.872	.003	36	view →
KIRC	DFS	Tertile	All	0.737	0.872	.009	30	view →
UCS	OS	Tertile	III,IV	0.791	0.339	.003	28	view →
LIHC	DFS	Tertile	II,III,IV	0.080	0.427	.019	18	view →
SKCM	DFS	Tertile	II,III,IV	0.812	0.676	.029	15	view →
LGG	DFS	Tertile	All	0.878	0.813	.043	7	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

LINC01916–LUAD (OS)

Open the LUAD breakdown →